Senetek releases Pyratin-6 and Pyratine XR  (March 2009) to treat crows-feet, wrinkles, fine lines, redness, skin dryness and discoloration.

Derived from plant cytokinins

The Company continues to garner media attention related to its September 2008 launch of Pyratine-6™ and its March 2009 launch of Pyratine XR™ at the American Academy of Dermatology's 67th Annual Meeting. Pyratine-6™ and Pyratine XR™ have been featured in magazines including Prevention, Dermatology Times, Inside Cosmeceuticals, Les Nouvelles Esthetiques and Skin Inc. and in radio and television spots in Las Vegas, Nevada and Baltimore, Maryland.

Commenting on media coverage of Pyratine-6™ and Pyratine XR™, Frank J. Massino, Chairman and Chief Executive Officer of Senetek PLC stated “The high-profile consumer and trade media placements for Pyratine-6™ and Pyratine XR™ have raised product and brand visibility in the medical community, as well as directly with consumers, increasing product awareness and demand. With additional media coverage slated for early 2009 and an ongoing public relations campaign, we are confident that Pyratine-6™ and Pyratine XR™ will attain the success we know is possible."

About Senetek PLC:
Senetek PLC (OTCBB:SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company’s extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company’s websites
www.senetekplc.com
www.pyratine-6.com
www.pyratinexr.com